Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BARD1 R112* |
| Therapy | Cisplatin + Olaparib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BARD1 R112* | neuroblastoma | sensitive | Cisplatin + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Lynparza (Olaparib) and Platinol (cisplatin) treatment inhibited viability of a neuroblastoma cell line expressing BARD1 R112* culture (PMID: 37688570). | 37688570 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37688570) | BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. | Full reference... |